Altered Expression of Adrenomedullin 2 and its Receptor in the Adipose Tissue of Obese Patients.
Adrenomedullin 2 (AM2) plays protective roles in the renal and cardiovascular systems. Recently, studies on experimental animals showed that AM2 is an adipokine with beneficial effects on energy metabolism. However, there is little information regarding AM2 expression in human adipose tissue. To investigate the pattern and regulation of AM2 expression and that of its receptor component in human adipose tissue, in the context of obesity and type 2 diabetes. We measured metabolic parameters, serum AM2 and expression of ADM2 and its receptor component genes in abdominal subcutaneous and visceral adipose tissue in obese (with or without type 2 diabetes) and normal-weight women. Serum AM2 was assessed before and 6-9 months after bariatric surgery. Expression/secretion of AM2 and its receptor was assessed in human adipocytes. ADM2 mRNA in both fat depots was higher in obese patients, whether diabetic or not. Although serum AM2 was significantly lower in obese patients, it was not changed after bariatric surgery. AM2 and its receptor complex were predominantly expressed by adipocytes, and expression of CALCRL, encoding a component of the AM2 receptor complex, was lower in both fat depots of obese patients. Incubating adipocytes with substances mimicking the microenvironment of obese adipose tissue increased ADM2 mRNA but reduced AM2 secretion into culture media and CALCRL mRNA expression. Our data indicate that AM2 signalling is suppressed in adipose tissue in obesity, involving lower receptor expression and ligand availability, likely contributing to insulin resistance and other aspects of the pathophysiology associated with obesity.